vs
Side-by-side financial comparison of Bluerock Homes Trust, Inc. (BHM) and CytomX Therapeutics, Inc. (CTMX). Click either name above to swap in a different company.
Bluerock Homes Trust, Inc. is the larger business by last-quarter revenue ($18.9M vs $18.7M, roughly 1.0× CytomX Therapeutics, Inc.). CytomX Therapeutics, Inc. runs the higher net margin — -0.8% vs -50.1%, a 49.3% gap on every dollar of revenue. On growth, Bluerock Homes Trust, Inc. posted the faster year-over-year revenue change (35.9% vs -25.7%). Bluerock Homes Trust, Inc. produced more free cash flow last quarter ($10.4M vs $-15.8M). Over the past eight quarters, Bluerock Homes Trust, Inc.'s revenue compounded faster (30.1% CAGR vs -15.9%).
Bluerock Homes Trust, Inc. is a U.S.-headquartered real estate investment trust that acquires, owns and operates a portfolio of high-quality single-family rental residential properties. It caters to middle-market renters across high-growth suburban markets, prioritizing regions with strong demographic fundamentals and sustained rental housing demand.
CytomX Therapeutics is a clinical-stage biotechnology company specializing in innovative cancer immunotherapies. It leverages its proprietary Probody technology platform to develop targeted therapies that activate exclusively in tumor microenvironments, minimizing off-target toxicities, with a pipeline covering multiple solid tumor indications and partnerships with leading global pharmaceutical firms.
BHM vs CTMX — Head-to-Head
Income Statement — Q4 FY2025 vs Q2 FY2025
| Metric | | |
|---|---|---|
| Revenue | $18.9M | $18.7M |
| Net Profit | $-9.5M | $-154.0K |
| Gross Margin | — | — |
| Operating Margin | -48.8% | -6.9% |
| Net Margin | -50.1% | -0.8% |
| Revenue YoY | 35.9% | -25.7% |
| Net Profit YoY | -29.9% | 97.6% |
| EPS (diluted) | $-0.75 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $18.9M | — | ||
| Q3 25 | $16.6M | — | ||
| Q2 25 | $16.8M | $18.7M | ||
| Q1 25 | $16.4M | $50.9M | ||
| Q4 24 | $13.9M | $38.1M | ||
| Q3 24 | $12.7M | $33.4M | ||
| Q2 24 | $12.5M | $25.1M | ||
| Q1 24 | $11.2M | $41.5M |
| Q4 25 | $-9.5M | — | ||
| Q3 25 | $-10.0M | — | ||
| Q2 25 | $-5.8M | $-154.0K | ||
| Q1 25 | $-7.3M | $23.5M | ||
| Q4 24 | $-7.3M | $18.9M | ||
| Q3 24 | $3.5M | $5.7M | ||
| Q2 24 | $-5.2M | $-6.5M | ||
| Q1 24 | $-3.2M | $13.8M |
| Q4 25 | -48.8% | — | ||
| Q3 25 | -57.6% | — | ||
| Q2 25 | -30.9% | -6.9% | ||
| Q1 25 | -42.6% | 44.4% | ||
| Q4 24 | -52.8% | 46.4% | ||
| Q3 24 | 27.9% | 12.3% | ||
| Q2 24 | -41.3% | -33.7% | ||
| Q1 24 | -28.4% | 28.1% |
| Q4 25 | -50.1% | — | ||
| Q3 25 | -60.0% | — | ||
| Q2 25 | -34.7% | -0.8% | ||
| Q1 25 | -44.7% | 46.2% | ||
| Q4 24 | -52.8% | 49.6% | ||
| Q3 24 | 27.9% | 17.2% | ||
| Q2 24 | -41.3% | -26.0% | ||
| Q1 24 | -28.4% | 33.3% |
| Q4 25 | $-0.75 | — | ||
| Q3 25 | $-0.94 | — | ||
| Q2 25 | $-0.66 | — | ||
| Q1 25 | $-0.67 | — | ||
| Q4 24 | $-0.65 | — | ||
| Q3 24 | $0.24 | — | ||
| Q2 24 | $-0.42 | — | ||
| Q1 24 | $-0.27 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $169.6M | $49.0M |
| Total DebtLower is stronger | $428.4M | — |
| Stockholders' EquityBook value | $128.7M | $119.9M |
| Total Assets | $1.2B | $175.1M |
| Debt / EquityLower = less leverage | 3.33× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $169.6M | — | ||
| Q3 25 | $2.1M | — | ||
| Q2 25 | $4.2M | $49.0M | ||
| Q1 25 | $3.0M | $47.6M | ||
| Q4 24 | $115.2M | $38.1M | ||
| Q3 24 | $155.1M | $40.6M | ||
| Q2 24 | $116.0M | $43.2M | ||
| Q1 24 | $92.3M | $36.2M |
| Q4 25 | $428.4M | — | ||
| Q3 25 | $415.9M | — | ||
| Q2 25 | $338.6M | — | ||
| Q1 25 | $336.5M | — | ||
| Q4 24 | $373.8M | — | ||
| Q3 24 | $122.5M | — | ||
| Q2 24 | $119.7M | — | ||
| Q1 24 | $120.2M | — |
| Q4 25 | $128.7M | — | ||
| Q3 25 | $131.7M | — | ||
| Q2 25 | $135.3M | $119.9M | ||
| Q1 25 | $137.1M | $25.0M | ||
| Q4 24 | $139.1M | $-456.0K | ||
| Q3 24 | $142.9M | $-23.5M | ||
| Q2 24 | $142.5M | $-31.2M | ||
| Q1 24 | $144.5M | $-31.7M |
| Q4 25 | $1.2B | — | ||
| Q3 25 | $222.1M | — | ||
| Q2 25 | $220.3M | $175.1M | ||
| Q1 25 | $186.2M | $98.5M | ||
| Q4 24 | $967.0M | $120.5M | ||
| Q3 24 | $800.8M | $139.0M | ||
| Q2 24 | $756.2M | $159.2M | ||
| Q1 24 | $727.4M | $184.7M |
| Q4 25 | 3.33× | — | ||
| Q3 25 | 3.16× | — | ||
| Q2 25 | 2.50× | — | ||
| Q1 25 | 2.45× | — | ||
| Q4 24 | 2.69× | — | ||
| Q3 24 | 0.86× | — | ||
| Q2 24 | 0.84× | — | ||
| Q1 24 | 0.83× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $27.8M | $-15.8M |
| Free Cash FlowOCF − Capex | $10.4M | $-15.8M |
| FCF MarginFCF / Revenue | 55.0% | -84.6% |
| Capex IntensityCapex / Revenue | 91.8% | 0.1% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $25.0M | $-77.7M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $27.8M | — | ||
| Q3 25 | $13.4M | — | ||
| Q2 25 | $13.9M | $-15.8M | ||
| Q1 25 | $951.0K | $-21.0M | ||
| Q4 24 | $9.1M | $-19.9M | ||
| Q3 24 | $1.7M | $-20.7M | ||
| Q2 24 | $1.3M | $-19.5M | ||
| Q1 24 | $1.1M | $-26.0M |
| Q4 25 | $10.4M | — | ||
| Q3 25 | $8.7M | — | ||
| Q2 25 | $8.8M | $-15.8M | ||
| Q1 25 | $-2.9M | $-21.2M | ||
| Q4 24 | $-253.0K | $-20.0M | ||
| Q3 24 | $-601.0K | $-20.7M | ||
| Q2 24 | $-654.0K | $-19.6M | ||
| Q1 24 | $-630.0K | $-26.2M |
| Q4 25 | 55.0% | — | ||
| Q3 25 | 52.4% | — | ||
| Q2 25 | 52.2% | -84.6% | ||
| Q1 25 | -17.6% | -41.6% | ||
| Q4 24 | -1.8% | -52.5% | ||
| Q3 24 | -4.7% | -62.1% | ||
| Q2 24 | -5.2% | -78.2% | ||
| Q1 24 | -5.6% | -63.1% |
| Q4 25 | 91.8% | — | ||
| Q3 25 | 28.5% | — | ||
| Q2 25 | 30.3% | 0.1% | ||
| Q1 25 | 23.4% | 0.2% | ||
| Q4 24 | 66.9% | 0.2% | ||
| Q3 24 | 18.0% | 0.1% | ||
| Q2 24 | 15.3% | 0.4% | ||
| Q1 24 | 15.5% | 0.3% |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | -0.89× | ||
| Q4 24 | — | -1.05× | ||
| Q3 24 | 0.47× | -3.61× | ||
| Q2 24 | — | — | ||
| Q1 24 | — | -1.89× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
BHM
| Residential Communities Segment | $11.4M | 61% |
| Scattered Single Family Homes Segment | $7.5M | 39% |
CTMX
| Bristol Myers Squibb Company | $11.6M | 62% |
| Astellas Pharma Inc | $4.6M | 25% |
| Regeneron Pharmaceuticals Inc | $2.1M | 11% |
